NASDAQ: PLRXPliant Therapeutics Inc Stock
$11.24+0.12 (+1.08%)
Updated Oct 8, 2024
PLRX Price
$11.24
Fair Value Price
$0.84
Market Cap
$683.41M
52 Week Low
$10.22
52 Week High
$19.62
P/E
-3.64x
P/B
1.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$185.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.23
Operating Cash Flow
-$137M
Beta
0.84
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PLRX Overview
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PLRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLRX ($11.24) is overvalued by 1,244.96% relative to our estimate of its Fair Value price of $0.84 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PLRX ($11.24) is not significantly undervalued (1,244.96%) relative to our estimate of its Fair Value price of $0.84 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PLRX due diligence checks available for Premium users.
Be the first to know about important PLRX news, forecast changes, insider trades & much more!
PLRX News
Valuation
PLRX fair value
Fair Value of PLRX stock based on Discounted Cash Flow (DCF)
Price
$11.24
Fair Value
$0.84
Overvalued by
1,244.96%
PLRX ($11.24) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PLRX ($11.24) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PLRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.64x
Industry
-119.06x
Market
27.24x
PLRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.74x
Industry
5.97x
PLRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$55.9M
Profit Margin
0%
PLRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$483.7M
Liabilities
$91.1M
Debt to equity
0.23
PLRX's short-term assets ($447.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLRX's short-term assets ($447.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$45.3M
Investing
$10.7M
Financing
$684.0k
PLRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLRX vs Biotech Stocks
Pliant Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.